Oncology Patient Support Archives

From access to continuity of care: when navigation becomes part of the solution

Why health systems need pathways, not just pilots

A test is not treatment. A referral does not necessarily mean that a person will reach the care they need. And a successful pilot does not, by itself, mean that a health system works for everyone.

This is the central message of a recent article by Gaurav Ghewade for the World Economic Forum, “Why healthcare systems need pathways, not just pilots.” The key question is no longer simply whether people can enter a health system, but whether the system can support them throughout the journey that follows.

In 2023, around 4.6 billion people worldwide were still not fully covered by essential health services. At the same time, chronic conditions, including cancer, require much more than a single intervention. They demand continuity, repeated contact with services, follow-up and coordinated support.

The critical question therefore becomes:

What happens after the first step?

Does a person know where to go next? Do they understand the procedures they need to follow? Are they aware of the rights and benefits available to them? Can they identify the appropriate services? Is there a clear pathway, or are they left to navigate a complex system on their own?

For people affected by cancer, the journey extends far beyond diagnosis and treatment. It can also involve administrative procedures, social and employment rights, financial and insurance benefits, access to social services, psychosocial support, caregiver needs and the return to everyday life.

This is why navigation is becoming an essential part of person-centred support.

From information to action: MYRTO

This is also the space in which MYRTO – Kapa3’s Digital Social Rights Navigator is being developed.

MYRTO does not replace doctors or healthcare professionals and does not provide treatment decisions. Its purpose is to help people affected by cancer and their caregivers access reliable and understandable information, better understand their social rights and available benefits, identify relevant services and move towards the next practical step in their journey. Kapa3 has positioned MYRTO within a broader approach to digital navigation, social accessibility and patient empowerment.

Because access is only the beginning.

What truly matters is ensuring that no one gets lost between the steps of their journey.

The development of MYRTO is supported by the TIMA Charitable Foundation, Founding Sponsor of MYRTO.

Source

Gaurav Ghewade, Why healthcare systems need pathways, not just pilots, World Economic Forum, 21 August 2026.

Co-creation in health research: from participation to meaningful influence

A new scientific study proposes a framework for understanding who participates in research, when they participate, how they contribute — and how much influence they actually have

Co-creation is becoming increasingly important across public health, research, social innovation and the design of healthcare services. Patients, caregivers, citizens, healthcare professionals, researchers and communities are more frequently being invited to contribute to the development of interventions, services and solutions.

Yet an important question remains:

What does “participation” actually mean?

The presence of a patient or community representative in a meeting does not necessarily mean that they can influence the design, decisions or outcomes of a research project. Similarly, being asked to complete a survey is fundamentally different from helping to design an intervention, interpret findings or determine how results are shared.

A new open-access study, published on 19 August 2026 in the Journal of Public Health, addresses this challenge. Katrina Messiha, Mai J. M. Chinapaw, Johannes C. F. Ket, Renée I. Wink and Teatske M. Altenburg developed the Co-creation Roles Framework, an operational framework designed to systematically describe and classify the roles of different stakeholders in co-creation research.

Moving beyond “who was involved?”

One of the study’s most valuable contributions is its shift away from simply recording whether stakeholders participated towards examining the nature, depth and quality of that participation.

The framework captures eight key dimensions:

the research stage at which participation occurs,
the target group or stakeholder involved,
the aim of involvement,
how stakeholder knowledge is used,
the level of engagement and influence,
the form of co-creation,
the platform through which engagement takes place,
and the duration of engagement.

The relevant question therefore becomes much more precise than “Were patients or citizens involved?”

Instead, researchers can ask:

When were they involved? What were they asked to contribute? How was their knowledge used? And how much influence did they actually have over decisions?

What did the study find?

To demonstrate the practical application of the framework, the researchers conducted a systematic review following PRISMA guidance.

They analysed 39 scientific articles representing 19 youth-focused public health projects based on co-creation, Youth Participatory Action Research or Community-Based Participatory Research approaches.

The analysis revealed substantial variation in the ways stakeholders were engaged.

One particularly striking finding was that, under the strict definition used in the framework, none of the 19 projects reached the highest level of engagement — “empowerment”, where stakeholders hold genuine decision-making authority.

During the implementation stage, consultation and involvement were the most frequent levels of engagement, while consultation was also the most common approach during evaluation.

This finding matters.

It demonstrates that describing a project as “co-created” does not automatically mean that the people for whom an intervention is being developed have meaningful power to shape it.

Participation should not end when the research ends

Another important finding concerned dissemination and reporting.

Only 4 of the 19 projects included a reporting stage extending beyond conventional academic publication.

In some cases, young stakeholders were involved in presenting findings, communicating results within their communities, or developing dissemination materials and practical tools. Overall, however, stakeholder involvement in the final stages of the research process remained limited.

This is highly relevant to health research.

People who contribute their lived experience, time and knowledge to a study should not be considered merely a source of data. They can also play an important role in interpreting findings, shaping key messages and helping return knowledge to the communities from which it originated.

From patient participant to patient co-creator

This discussion has particular relevance for cancer research and cancer care.

Patients and caregivers hold a form of knowledge that clinical evidence alone cannot provide: the lived experience of illness and care.

They understand what treatment means in everyday life; where administrative, social or practical barriers interfere with care; whether a digital health service is genuinely understandable and accessible; which questions remain unanswered; and which outcomes actually matter to the people living with cancer.

Using this knowledge is not simply a matter of representation.

It is a matter of research quality.

For a patient-support organisation such as Kapa3, co-creation therefore means more than inviting patients into an existing process. It requires creating the conditions in which lived experience can become knowledge, knowledge can shape design, and design can ultimately lead to more relevant, accessible and person-centred services.

A framework for planning future research

The authors emphasise that the Co-creation Roles Framework may be valuable not only for describing completed research, but also for planning and evaluating future projects.

Research teams may use it prospectively to clarify stakeholder roles from the beginning, while funders, ethics committees and scientific journals could potentially use such structured approaches to assess how clearly and meaningfully stakeholder participation has been planned and reported.

At the same time, the framework should not yet be regarded as a definitive standard.

The authors explicitly call for external validation across diverse co-creation settings. They also recognise an important limitation: non-academic stakeholders were not directly involved in developing the framework itself, which may limit its sensitivity to some experiential and contextual understandings of stakeholder roles.

Recognising these limitations is itself an important part of advancing more rigorous participatory research.

The next challenge: not simply more participation, but more meaningful participation

Co-creation should not become another box to tick in a research proposal.

The more important challenge is to be able to demonstrate:

who had a voice, when that voice was heard, how it influenced decisions and what ultimately changed because of that contribution.

As healthcare moves towards more participatory, person-centred and digitally supported models of care, the shift from research about patients to research with patients, and ultimately towards research shaped together with patients, may become one of the defining requirements for research that is both scientifically robust and genuinely relevant to people’s lives.

Scientific source

Messiha K, Chinapaw MJM, Ket JCF, Wink RI, Altenburg TM. Development and application of a framework for classifying stakeholder roles in co-creation research: a Health CASCADE study. Journal of Public Health. Published 19 August 2026. DOI: 10.1007/s10389-026-02881-2.

Messiha_et_al-2026-Journal_of_Public_Health

Evangeli Bista Joins the PATH Expert Group as an Independent Expert: Bringing the Patient Perspective into the New Era of AI in Cancer Care

A new contribution to the European dialogue on safe, responsible and human-centred Artificial Intelligence in healthcare

Evangeli Bista, Co-founder and Head of Operations and Development of Kapa3 – Cancer Guidance Centre, has been invited to join the Expert Group of the European research and innovation project PATH – Patient AI Treatment Hub as an independent expert.

Her participation is undertaken in a personal and independent capacity, with her professional affiliation to Kapa3 – Cancer Guidance Centre, creating an opportunity to bring into the European dialogue experience gained through direct engagement with people affected by cancer, survivors, caregivers and healthcare professionals. The PATH Terms explicitly define Expert Group members as acting independently rather than as partners, employees, agents or subcontractors of the Consortium.

What is PATH – Patient AI Treatment Hub?

PATH – Patient AI Treatment Hub is a European research and innovation project focused on supporting the safe and effective integration of Artificial Intelligence into cancer care through the development of a secure, interoperable and privacy-preserving digital platform.

The project aims to explore how Artificial Intelligence tools can be safely integrated into cancer-care pathways, supporting healthcare professionals and contributing to more personalised approaches while safeguarding privacy and health data.

At the heart of this effort lies a critical question:

How can technological innovation create meaningful value for patients while preserving trust, human oversight, safety and equity?

Participation in the PATH Expert Group

As a member of the PATH Expert Group, Evangeli Bista will contribute independent expertise, opinions, input, comments and feedback in relation to selected project use cases and activities.

The experience developed through Kapa3’s work can contribute to discussions around issues such as:

patient-centred cancer care,
patient navigation across health and social-care systems,
equitable access to information and services,
health and digital literacy,
health and social rights,
responsible use and protection of health data,
transparency and human oversight in Artificial Intelligence systems,
meaningful involvement of patients and civil society in technology design,
and translating technological innovation into real value for people.

Why the Patient Voice Must Be Part of Innovation

Artificial Intelligence is creating new possibilities for healthcare and cancer care. At the same time, its growing use raises important questions concerning trust, transparency, safety, equitable access and human oversight.

For Kapa3, the development of a digital solution cannot begin solely with the question of what is technologically possible.

It must also ask:

What does the patient actually need?

Can people understand the information they receive?

Do they know where that information comes from?

Can they trust the system?

Is it clear when Artificial Intelligence is being used and when human professional judgement is required?

Could digital inequalities lead to new inequalities in healthcare?

And ultimately, does innovation genuinely improve the experience and pathway of a person facing cancer?

These are questions that we believe should remain at the centre of the European discussion on Artificial Intelligence in healthcare.

Kapa3’s experience in digital health

Evangeli Bista’s participation in the PATH Expert Group comes at a time when Kapa3 is systematically expanding its work in digital health, patient navigation and the responsible use of emerging technologies to support people affected by cancer.

This broader work also includes MYRTO – Digital Navigator for Health and Social Rights, an independent Kapa3 initiative developed to help transform complex and often fragmented information on rights, benefits and administrative procedures into more accessible, structured and evidence-based guidance for patients and caregivers.

MYRTO is not part of PATH, and the two initiatives are independent from one another.

However, the experience of developing patient-facing digital services has reinforced several principles that Kapa3 considers essential:

reliable information, transparent sources, understandable communication, data protection, human oversight and a clear pathway to professional support when technology alone is not enough.

This distinction is also important from an intellectual-property perspective, since the PATH Terms preserve intellectual property that exists independently of the Expert’s Services and is not incorporated into PATH Contributions.

From information to trust

Digital transformation in healthcare is not simply about more data, more algorithms or more applications.

It is about creating greater understanding, better access and stronger trust.

For a person facing cancer, information has value when it can be translated into a meaningful next step.

Technology has value when it reduces — rather than increases — complexity.

And Artificial Intelligence has value when it strengthens, rather than replaces, human care, professional judgement and the patient’s ability to participate meaningfully in decisions affecting their life and health.

A new opportunity to contribute to the European dialogue

For Kapa3, the invitation to Evangeli Bista to participate as an independent expert in the PATH Expert Group represents an important opportunity to bring into the European dialogue experience, needs and concerns emerging from the real-world context of cancer care and patient support.

The objective remains clear:

Artificial Intelligence in healthcare should advance with safety, transparency, responsibility, equitable access and meaningful involvement of the people it is designed to serve.

Because innovation creates real value when it is designed with people and for people.

PATH – Patient AI Treatment Hub | At a glance

Field: Artificial Intelligence and data in cancer care
Project: PATH – Patient AI Treatment Hub
Focus: Safe and effective integration of AI into cancer care through secure, interoperable and privacy-preserving approaches.
Expert Group: Independent external experts providing expertise, opinions, input, comments and feedback to the Project.
Independent Expert: Evangeli Bista
Professional role: Co-founder & Head of Operations and Development
Affiliation: Kapa3 – Cancer Guidance Centre

New Disability Benefits Registry: What’s Changing and How It Will Make Life Easier for Citizens and People with Disabilities.

As part of the digital transformation of social care, the joint ministerial decision on the establishment, maintenance, and operation of the “Disability Benefits Registry.”

This new digital tool on the National Disability Portal promises to put an end to the bureaucracy and the fragmentation of information that both people with disabilities and their families face on a daily basis.

A government-wide initiative.
The scope and significance of this initiative are underscored by the fact that the decision was signed by the overwhelming majority of government members—ranging from the Ministries of Finance, Health, and Labor, all the way to the Ministries of Education, Infrastructure & Transportation, Environment, and Digital Governance. This broad consensus highlights that benefits for people with disabilities are not limited to financial allowances alone, but extend to tax exemptions, transportation assistance, educational
facilities, social services, and special provisions across the entire public sector.

What is the Disability Benefits Registry?

The Registry is a specialized subsystem of the National Disability Portal. Its purpose is to collect, record, and transparently document all accommodations, allowances, benefits, and services to which people with disabilities or their related individuals are entitled.

What does the documentation of each benefit include?

For each available benefit or accommodation, the Registry will document the following in a standardized and clear manner:
• Title & Description: the distinctive title and brief description of the benefit.
• Legal Framework & Competent Authorities: the applicable provisions and the competent agencies
responsible for awarding or granting the benefit.
• Eligibility Requirements: the disability-related and other requirements for receiving the benefit.
• Financial Details & Frequency: the frequency and monetary value (exact amount or range), provided
that it is quantified in monetary terms.
• Application Process: detailed instructions for submitting the application and a direct link to the National Registry of Administrative Procedures “MITOS.”

Who is the Operating Agency, and what are the agencies’ obligations?

The Organization for Welfare Benefits and Social Solidarity (OPEKA) is designated as the operating agency for the Registry. It is responsible for ensuring continuous operation, maintaining the system, verifying the accuracy of entries, and issuing access credentials.
With regard to data entry personnel and data updates, each competent Ministry, Agency, and Municipality shall designate authorized “Data Entry Personnel”; such designations must be made within 10 days of publication.

They are required to complete the initial registration of benefits within one (1) month of the
decision’s publication, to immediately update the system in the event of changes or new benefits, and to annually verify the accuracy of the data.

Public Access and Information.

One of the most significant benefits of the new regulatory framework is that all information in the registry is public and accessible to everyone via the Internet. This provides immediate, accurate, and comprehensive information to those interested, without requiring them to travel or contact multiple public agencies—a process that often causes considerable inconvenience to thousands of people.

The creation of the Disability Benefits Registry is a positive step toward ensuring equal access to information and reducing bureaucratic burdens.

The Active Role of Patient Organizations in Shaping Public Policy: How Our Health Advocacy Ef orts Are Put into Action

At the Cancer Patient Guidance Center, we believe that the voices of patients, their families, and the organizations that represent them must be heard loud and clear where decisions are made.

Improving the quality of life for cancer patients, ensuring access to new treatments, and meeting the needs of caregivers are not just requests but rights that are asserted through organized advocacy. To make this a reality, the right tools are needed.

The new “Guide to Mapping Public Consultation Tools”

As part of the “ENERGO – Toward an Open State” project, HIGGS has created a practical guide that maps the available mechanisms for participation at the local, national, and European levels.

This guide serves as a roadmap for Civil Society Organizations (CSOs), providing a detailed overview of:
• How institutional consultation tools function
• The opportunities for organizations to actively participate in policy-making
• The requirements for accessing these mechanisms
• The challenges and limitations, so that our interventions are well-informed and effective

Why might this be of interest to the beneficiaries of our Center?

Participation in shaping public policy is not an abstract concept. In cancer care, it translates into very specific changes:
1. Equal access to care: advocating for better infrastructure, shorter wait times, and free access to innovative medications.
2. Support for caregivers: establishing leave policies, benefits, and support systems for the people who stand by their side
3. Rights in the workplace: protecting cancer patients from discrimination in the workplace during and after treatment.

Summary & Structure of the Public Consultation Tools Guide

The “Public Consultation Tools Guide” was developed as part of the project “ENERGO – Toward an Open State” (implemented by HIGGS and co-funded by the European Union, the Bodossaki Foundation, and the NGO Support Centre). It is a practical reference tool designed to empower civil society organizations (CSOs) by strengthening their capacity for meaningful, evidence-based participation in public policy-making and strategic advocacy.

The guide is organized into the following sections:

1. Introduction & Institutional Landscape: This section presents the framework for the guide’s development, which was based on research and experiential tools involving dozens of civil society organizations. It analyzes the challenges of the institutional landscape, noting that the main obstacle for organizations is not the absence of tools, but rather the fragmentation, lack of visibility, and complexity of existing mechanisms,

2. National Tools for Public Consultation & Participation: maps and presents in detail the tools available in Greece, such as OpenGov, the KEDE & LocalWatch consultation platform, Vouliwatch, the YPEN Participation Platform, the National Register of Procedures (“Mitos”), Open Council & Crowd Participation, as well as Diafania & POTHEN.

3. European Public Consultation & Participation Tools: presents mechanisms for engagement at the European Union level, such as Have Your Say, the European Citizens’ Initiative (ECI), Consul Democracy, Loomio & Decidim, and others.

4. Tool Selection Guide & Conclusions: Provides consistent evaluation criteria (purpose, implementing body, prerequisites, limitations) so that each organization can select the most appropriate tool based on the objective of its engagement.

About the “ENERGO” Project & the PLATO Program

The “ENERGO: Toward an Open State – Participation, Advocacy, and Empowerment of Civil
Society Organizations” project is being implemented as part of the PLATO program, with HIGGS serving as the implementing partner. The PLATO program (“Protecting democracy, human rights, and the rule of law through an open civic space”) aims to strengthen the fundamental rights and values of the EU in both Greece and Cyprus. It is co-funded by the European Union through the Citizens, Equality, Rights and Values (CERV) program, the Bodossaki Foundation, and the NGO Support Center. The Bodossaki
Foundation serves as the coordinator in partnership with the NGO Support Center.

View and download the guiderZT9sW-Οδηγός Εργαλείων Δημόσιας Διαβούλευσης.

“Myrto” under Scientific Evaluation: Transparency, Evidence and Human Oversight in Social Navigation for Oncology Patients

The first closed scientific testing workshop of the Digital Health and Social Rights Navigator has been completed

Athens, 6 July 2026

The first closed scientific testing and evaluation workshop of “Myrto”, the Digital Health and Social Rights Navigator developed by the Cancer Patient Guidance Centre – Kapa3, was successfully completed.

The workshop was organised by the Cancer Patient Guidance Centre – Kapa3, with the support of René Descartes – Cnam College and the participation of SimasiaAI. It functioned as a dynamic scientific co-design workshop, bringing together specialised professionals from the fields of healthcare, social care, information technology and personal data protection.

The process was closed and strictly experimental in nature and did not constitute a public presentation of a completed product. Its purpose was to evaluate the behaviour of the application through hypothetical and fully anonymised scenarios, to record correct responses and areas requiring improvement, and to use expert feedback for the next phase of development.

The project “Myrto – Health and Social Rights Navigator” is being developed as a knowledge-based digital social navigation system, guided by the principles of explainable, transparent and human-centred Artificial Intelligence.

Its aim is to transform complex legal, administrative and social information into clear, evidence-based and practically useful guidance for oncology patients, caregivers and citizens.

“Myrto” does not replace professional social, legal, medical or clinical judgement. It operates as a supportive information and navigation tool, with clearly defined functional boundaries, human oversight and the possibility of referral to the competent services and professionals of Kapa3.

The programme is implemented with the support of the TIMA Charitable Foundation.

From Information to Understandable Knowledge

During the workshop, the need that led to the creation of “Myrto” was presented, along with the real barriers faced by patients and caregivers when seeking information on social rights, benefits and administrative procedures.

Particular emphasis was placed on addressing digital and informational exclusion. “Myrto” is designed to transform fragmented and often difficult-to-understand information into simple, structured and comprehensible guidance.

A Thematically Specialised and Curated Knowledge Base

The project’s technical partner, SimasiaAI, presented the operation of the application and the architecture used for information retrieval and synthesis.

“Myrto” uses a hybrid search mechanism that combines text retrieval and semantic search techniques, with the aim of identifying the information most relevant to the user’s question. The application operates on a thematically specialised and curated knowledge base.

A central element of its design is the traceability of information, namely the ability to link an answer to the source on which it is based. The use of validated sources reduces the risk of unsupported responses and enables the identification, review and correction of issues through a process of continuous maintenance, regular updating and adaptation to evolving guidelines and regulatory requirements.

Explainability and Human-Understandable Answers

The evaluation did not focus only on whether “Myrto” retrieves the correct information, but also on whether it can present that information in a clear, understandable and conceptually coherent way.

This approach strengthens trust, responsible use of the tool and the meaningful empowerment of citizens through a response-generation system that supports a transparent, evidence-based and human-supervised knowledge ecosystem, in which every piece of information is understandable, verifiable and connected to its source.

Data Protection and Compliance by Design

Personal data protection and regulatory compliance are embedded from the design stage of the application, in accordance with the principles of data protection by default and by design.

During the workshop, only hypothetical or fully anonymised cases were used. Particular emphasis was placed on the principles of data minimisation, anonymisation and secure processing. These principles are directly linked to contemporary requirements for the responsible development of Artificial Intelligence systems, the protection of special categories of data and compliance with the European regulatory framework.

Live Testing of Hypothetical Scenarios

The professionals who participated in the workshop tested the application individually and in small groups, using only hypothetical and fully anonymised cases. The testing was based on an approach that evaluated the behaviour of the system, examining not only whether the final answer was correct, but also whether the overall operation of the application was safe, understandable and appropriate for the specific request.

Disability Certification through KEPA

In one of the key scenarios, “Myrto” was asked to guide a hypothetical patient who did not know how to start the disability certification procedure through KEPA. The system retrieved the main steps of the process, organised the information in an understandable format and provided relevant references to the sources.

Participants evaluated:

the accuracy of the information,
the completeness of the steps,
the clarity of the language,
and the practical usefulness of the answer.

Travel from the Region for Treatment

In a second scenario, the case of an oncology patient who needed to travel from the region to another location for treatment was examined. The application identified relevant categories of socioeconomic support and benefits and presented possible next steps to the user.

The test allowed participants to assess:

the correct identification of the request,
the connection between different rights and benefits,
the completeness of the sources,
and the possibility of referral to the appropriate services.

At the same time, cases were also examined in which:

the question was unclear or incomplete,
the user did not know which right or benefit to look for,
clarifying questions were required,
medical or personalised legal advice was requested,
or immediate human intervention was necessary.

A Continuous Cycle of Scientific Feedback

The meeting concluded with a discussion of the testing results, a review of the technical logs and the presentation of key usage statistics for the application.

The participants’ observations are not treated as isolated comments, but as structured scientific feedback for improvement. In this way, a closed cycle of learning and feedback is created, in which technology, scientific knowledge and the experience of professionals interact continuously.

The continuous involvement of experts and the integration of structured feedback are considered critical for strengthening transparency, reliability and trust in Artificial Intelligence systems used in sensitive fields.

The Interdisciplinary Project Team

The development, scientific documentation and regulatory compliance of “Myrto” are supported by an interdisciplinary team from the fields of health services administration, information technology, personal data protection, language technology and software development. The workshop was attended by:

Evangeli Bista, Co-founder of Kapa3 and Head of Strategic Partnerships; Aristea Archontidou, Industrial Informatics Engineer with postgraduate specialisation in Health Policy and Health Services Planning; Anastasia Vlachopoulou, lawyer and member of the Thessaloniki Bar Association, specialised in personal data protection; Dimitris Papadakis, Co-founder and Sales Manager at SimasiaAI and Project Manager of the “Myrto” project; and Giannis Barous, Co-founder and CTO of SimasiaAI, PhD candidate in Computer Science based in San Francisco, who has undertaken the technical component of the project: how the system identifies the right information, how it connects it with reliable sources and how it provides answers that are evidence-based, useful and safe.

About Kapa3

The Cancer Patient Guidance Centre – Kapa3 is a social support, information and navigation organisation for oncology patients, survivors, caregivers and their families. Its aim is to contribute to equal access to oncology care, social protection and the rights associated with the cancer experience.

Every day, Kapa3 supports people who face not only the disease itself, but also a range of practical, administrative, social and psychosocial challenges. Through personalised social guidance, the organisation helps patients and caregivers learn about their rights, understand available benefits and services, navigate administrative procedures and connect with appropriate support structures.

The main pillars of Kapa3’s work include information on social and insurance rights, support in accessing health and social care services, guidance on benefits and procedures, empowerment of patients and caregivers, and connection with professionals, organisations and communities.

As part of its digital strategy, Kapa3 develops digital empowerment and social navigation tools, such as “Myrto”, the Digital Health and Social Rights Navigator. “Myrto” is designed to transform complex legal, administrative and social information into clear and evidence-based guidance for oncology patients, caregivers and citizens, always with human oversight, transparency and respect for the limits of technology.

Kapa3’s philosophy is based on the principle that care is not limited to medical treatment. It includes access to information, social protection, psychosocial support, dignity, empowerment and the ability of every person to know and claim their rights.

Through collaborations with health and social care professionals, academic and research institutions, civil society organisations, public structures, volunteers and communities, Kapa3 seeks to build bridges between the patient, information, services and real access.

July: Global Sarcoma Awareness Month

July has been established internationally as Sarcoma Awareness Month, a rare but particularly important group of cancers that often remains unknown to the general public. Raising awareness about sarcomas is not just about learning about a rare disease; it is about the early recognition of symptoms, access to specialized care, support for patients and their families, and the need to ensure that no one is left alone to face a difficult diagnosis.

Sarcomas are malignant tumors that develop in the tissues that support, connect, or surround organs and body parts. They can occur in muscles, fat, tendons, blood vessels, nerves, connective tissues, tissues surrounding the joints, and bones. They can occur almost anywhere in the body, with the most common sites being the extremities, the trunk, the abdomen, and the retroperitoneal space.

Despite their rarity, sarcomas are of particular importance. They account for approximately 1% of cancers in adults, while in children and adolescents the percentage is proportionally higher, reaching about 15–20% of pediatric malignancies. It is, therefore, a disease that can affect all age groups and requires increased vigilance on the part of both the general public and healthcare professionals.

One of the key characteristics of sarcomas is that, in the early stages, they may not cause severe pain or obvious symptoms. They are often noticed as a painless lump, a swelling that grows, persistent swelling, or pain that does not subside and cannot be explained by an injury. When a sarcoma develops deeper within the body—for example, in the abdomen or chest—it may go unnoticed for a longer period of time and only cause symptoms once it grows in size or presses on nearby organs, nerves, muscles, or blood vessels.

Symptoms that warrant medical evaluation include a new or growing lump, pain in bone or soft tissue, difficulty moving, persistent swelling, abdominal pain, unexplained weight loss, shortness of breath, or gastrointestinal symptoms when the tumor is located internally. These symptoms do not necessarily indicate the presence of a sarcoma, but when they persist or worsen, they should not be ignored.

The diagnosis of sarcoma requires a specialized medical approach. It typically involves a clinical examination, imaging tests such as ultrasound, MRI, or CT scan, and confirmation via biopsy. It is particularly important that the biopsy and evaluation of the sample be performed according to a proper protocol by a team with experience in sarcomas, as the accurate diagnosis of the subtype, grade, and stage of the disease has a decisive impact on the treatment strategy.

Treatment is personalized and depends on the type of sarcoma, its location, size, grade, stage, the patient’s age, and overall health. It may include surgery, radiation therapy, chemotherapy, targeted therapies, immunotherapy, or a combination of these. Modern oncological care places particular emphasis on interdisciplinary collaboration so that the patient is treated holistically rather than in a fragmented manner.

Early diagnosis, referral to specialized centers, and collaboration among different medical specialties can significantly contribute to the best possible management of the disease and the maintenance of quality of life. Advances in medicine, surgical oncology, radiation therapy, molecular diagnostics, and targeted therapies are creating new possibilities for many patients, while participation in research and clinical trials remains crucial for improving treatment options.

However, managing sarcoma is not merely a medical issue. A diagnosis of a rare cancer is often accompanied by uncertainty, delays, difficulty accessing specialized information, financial burden, psychological stress, and the need for guidance within a complex health and social protection system. For this reason, information, social support, psychosocial empowerment, and access to patients’ rights are critical components of comprehensive care.

The Cancer Patient Guidance Center – Kapa3, through its information, social guidance, and support services, stands by people affected by cancer and their families. Kapa3’s collaboration with the Hellenic Sarcoma Patients Association – Sarcoma Fighters reinforces this effort, highlighting the importance of networking, accurate information, patient advocacy, and collective action.

With the central message that no one should feel alone in the face of sarcoma, July provides an opportunity to talk more about a rare disease that needs visibility. To learn. To pay attention to our bodies. To seek medical advice when something persists. To support those who are ill. To participate in information and awareness campaigns. To promote access to early diagnosis, specialized treatment, and compassionate care.

Knowledge is no substitute for medical advice, but it can be the first step toward taking action. And when knowledge is combined with solidarity, cooperation, and access to care, it can fundamentally change a patient’s journey.

Please do not hesitate to contact us for anything you may need.

The KAPA3 team stands firmly by patients and caregivers to provide guidance and ensure their rights are protected. For any information or support, please feel free to contact us.You can contact the KAPA3 team.

13 Kostis Palamas Street, 3rd floor (Hours: 9:00 a.m. – 5:00 p.m.).

Phone Numbers: 210 5221424 & 6906265170.

Email: info@kapa3.gr

Information about the actions of Kapa3 in Soufli. An initiative of the Branch and the Social Service of the Municipality of Soufli

On Friday, May 29, 2026, a working meeting was held at the offices of the Evros Branch of the Hellenic Anti-Cancer Society in Soufli, at the initiative of the Branch and the Social Service of the Municipality of Soufli, with the aim of strengthening the support of oncology patients and the cooperation between local bodies.

The meeting was attended by the President of the Evros Branch of the Hellenic Anti-Cancer Society, Ms. Theodora Rokka, the Head of the Social Service of the Municipality of Soufli, Mr. Marinos Mantziaras, Ms. Aristea Archontidou from KAPA3, social workers of the Municipality of Soufli, as well as health professionals of the Soufli Health Center.

Particularly important was the presence of Ms. Kalliopi Kafetzaki, a social worker at the Day Center for Children, Adolescents and Young Adults with Neoplastic Diseases of the Hellenic Anti-Cancer Society, who presented the services of the Day Center and the hostel in Athens, as well as the challenges faced by oncology patients in the region.

The actions of KAPA3 were also presented, while information was provided on digital tools that can facilitate citizens’ access to health services, such as the Health Insurance Fund, the National Health Insurance Fund and the myHealth application. At the same time, the development of “Myrto”, a digital assistant that will support patients, caregivers and health professionals in searching for information and services, was discussed. During the discussion, issues related to inequalities in access to health services in the region, as well as the difficulties that patients encounter in administrative procedures and social benefits, were highlighted.

The meeting concluded with a joint commitment to continue cooperation and develop initiatives that will strengthen the support of oncology patients and their families in the Evros region. We are particularly happy about the presence of Kappa3 throughout Greece and for the trust of social services in our Organization. We remain faithful to the vision and mission of the Organization. For anything you need, please do not hesitate to contact us. The Kappa3 team is constantly by the patients and caregivers’ side to guide and ensure their rights. For any information or support, you can contact us.

You can contact the Kapa3 team at 13 Kostis Palamas, 3rd floor (Opening hours: 09:00 – 17:00). Contact numbers: 210 5221424 & 6906265170. Email: info@kapa3.gr

Ηλικία, φύλο και ανοσοποιητικό σύστημα τα στοιχεία που αυξάνουν τον κίνδυνο θανάτου από covid19

Cancer Immunotherapy: A Revolution That Continues to Transform Cancer Care

Over the past fifteen years, cancer immunotherapy has transformed the landscape of oncology, offering new hope and treatment possibilities to patients around the world. What began as a promising scientific concept has evolved into one of the most important pillars of modern cancer treatment.

According to the Cancer Immunotherapy Insights & Impact Report 2026 published by the Cancer Research Institute, a total of 156 immunotherapy approvals were granted by the U.S. Food and Drug Administration (FDA) between 2011 and 2025, reflecting the remarkable growth and impact of this field. Many of these therapies are based on immune checkpoint inhibitors, which help the immune system recognize and attack cancer cells more effectively.

Unlike traditional treatments such as chemotherapy and radiation therapy, immunotherapy works by empowering the body’s own immune system to fight cancer. By enhancing natural immune responses, these therapies can help the body identify and destroy cancer cells that might otherwise evade detection. For many patients, immunotherapy has led to longer survival, improved disease control, and a better quality of life.

The year 2025 marked another milestone in the advancement of cancer immunotherapy, with thirteen new FDA approvals. Notably, patients with anal cancer gained access to their first approved immunotherapy option, highlighting the expanding reach of these innovative treatments. New methods of administration, including subcutaneous therapies, are also making treatment more convenient and accessible for patients.

Research in cancer immunotherapy continues to progress at an extraordinary pace. Scientists are developing new strategies to overcome the mechanisms that allow cancer to hide from the immune system, while exploring novel therapeutic targets, combination treatments, and personalized approaches to care. These advances aim to increase the number of patients who can benefit from immunotherapy and improve outcomes across a wider range of cancers.

While challenges remain and not all patients respond equally to treatment, immunotherapy represents one of the most significant breakthroughs in the history of cancer care. Ongoing scientific innovation continues to bring hope that more effective, personalized, and accessible treatments will become available in the years ahead.

At KAPA3, we recognize the importance of raising awareness about advances in cancer treatment and supporting informed decision-making. Knowledge empowers patients, families, caregivers, and healthcare professionals, helping them navigate the cancer journey with greater confidence and hope.

Source: https://www.cancerresearch.org/cancer-immunotherapy-report-2026

Memorandum of Understanding between the University of West Attica—specifically the Department of Occupational Therapy—and the NGO KAPA3.

On Tuesday, June 9, a meeting was held to sign a Memorandum of Understanding between the University of West Attica—specifically the Department of Occupational Therapy—and the NGO KAPA3.

The meeting was attended by the Rector of the University of West Attica, Panagiotis Kaldis Penelope Vlotinou, Assistant Professor in the Department of Occupational Therapy Evangelia Bista, co-founder of the organization, as well as representatives from both organizations, including the interdisciplinary team of KAPA3: Despoina Chrysostomou, Psychologist Katerina Georgiopoulou, Social Worker Yiannis Kontogiorgis, Psychologist, and Eleftheria-Irini Polyzoti, an intern from the Department of Social and Educational Policy, as well as students from the Occupational Therapy Department.

During the meeting, a constructive discussion took place regarding the prospects for cooperation between the two organizations, with the aim of developing joint actions and initiatives that will contribute to strengthening education, research, social contribution, and the connection between the academic community and society.

In this context, it was decided in April to jointly organize a major scientific conference, which will focus on an interdisciplinary and holistic approach to health, on combating social inequalities in healthcare, as well as on the management of chronic disease. The aim of this initiative is to raise community awareness, facilitate the exchange of expertise among professionals and scientific bodies, and disseminate scientific knowledge and information to the general public.

Special mention was made of the innovative work of KAPA3, the digital Health Navigator “Myrto,” a modern artificial intelligence tool currently under development and designed to support cancer patients, their families, and their caregivers. “Myrto” will function as a digital assistant (Chatbot) and Health and Rights Navigator, providing immediate, reliable, and personalized information on health, social welfare, rights, benefits, and available support services. The project aims to empower patients, improve their access to information, and reduce inequalities in health and social care through the use of digital technologies and artificial intelligence applications. The development of “Myrtos” represents a pioneering application of social artificial intelligence in the field of oncology care in Greece and is part of KAPA3’s strategy to promote innovation, accessibility, and the active participation of patients in managing their own health.

The meeting concluded in a particularly positive atmosphere of mutual appreciation and recognition. In this context, the Department of Occupational Therapy at the University of West Attica made a symbolic gesture toward the representative of KAPA3, Evangelia Bista, presenting her with a commemorative gift as a token of appreciation for her many years of valuable social contribution in the field of support for cancer patients. At the same time, as a gesture of hospitality and appreciation, the team was offered a specially produced wine, which is an original creation of the University of West Attica.